ZYDUS LIFESCIENCES LTD Q4 RESULTS

Apar Industries shares zoom 8% after company reports Q4 results, announces Rs 51 dividend

Apar Industries recorded a fresh 52-week high on Tuesday apparently propelled by its Q4 revenue growth of 9% YoY. Its PAT, however, declined 3% YoY. The stock has zoomed 208% in the last one year.

Zydus Wellness shares rally nearly 4% after reporting PAT at Rs 150 crore; declares Rs 5 dividend

Zydus Wellness shares surged 3.8% on BSE, reaching a new 52-week high at Rs 1,750.20 following a 4% YoY rise in Q4 FY24 profit after tax to Rs 150.3 crore. The board announced a dividend of Rs 5 per share, with the record date set for July 19.

Q4 results this week: Zomato, Airtel, M&M among 501 companies set to announce earnings this week

Some notable companies that will announce their earnings this week include Varun Beverages, Zomato, Airtel, Siemens, Power Finance Corp, Mahindra and Mahindra, HAL, and JSW Steel, among others. Overall, around 501 companies are set to release their quarterly numbers this week.

Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback

Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.

Zydus Lifesciences Q3 Results: Firm beats profit estimates; approves shares buyback

​Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.

Supriya Lifesciences Q3 Results: Net profit triples to Rs 30 crore

Revenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA margin of 29.6% in Q3FY24, as opposed to 13.4%, an improvement of 1620 basis points.

Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios

There are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to stay in the game and cash on the balance sheet matter most. When the tide turns in favor of that sector, these large companies are able to make most of it. One sector which has gone through a phase of realignment of business and readjustment of valuations for many years and has once again come in limelight is the pharma space. Right from ability to deal with USFDA, not rely just on product segment to how to deal with uncertainty of supply chain which is dependent on China, Indian pharma companies have come a long way.

Wipro Q3 Results: Consolidated PAT drops 12% YoY to Rs 2,694 crore; Re 1/share interim dividend announced

Wipro Q3 Results: Wipro reported disappointing Q3 results, with a decline in net profit and revenue. The company's consolidated net profit decreased by nearly 12% YoY to Rs 2,694 crore, while the consolidated revenue dropped 4.4% to Rs 22,205 crore. The board recommended an interim dividend of Re 1 per share. For the nine months ended December, Wipro's consolidated revenue rose by only 0.4% to Rs 67,552 crore, while the net profit declined by nearly 1% to Rs 8,211 crore. Wipro expects revenue from its IT Services business to be in the range of $2.62 billion to $2.67 billion for the quarter ending March.

Good for all market conditions: 6 largecap stocks with right mix of RoE & RoCE

There is sunshine all around, better than expected GDP numbers, further decline in oil prices, falling US bond yields and clear indication from RBI that it is in no mood to increase interest rates any further. So while macros are bullish and could not get better, it is time to spend some time in understanding what stocks are you buying and why that stock at this point of time only. Also if one is thinking about increasing the exposure it would be better to stay with large caps as they would be able to weather any storm which might emerge due to any reason.

Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs

The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago

Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 crore

Revenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 40.6% YoY to Rs 1146 crore. On QoQ, EBITDA dropped 23.9%.

Zydus Q2 Results: Profit jumps on strong domestic, US demand

India's generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.

Q2 results this week: Adani Ports, Tata Power, LIC, RVNL, M&M and others

Power Grid, Shree Cements, Trent, Zydus Lifesciences, Info Edge (India), Indian Railway Catering & Tourism Corporation, Cummins India, Alkem Laboratories, UNO Minda, Prestige Estates Projects, among others will release their Q2 earnings on November 7

Zydus Lifesciences Q1 Results: Net profit doubles to Rs 1,087 crore, revenue jumps 30%

US business grew by 57% YoY at Rs 2454 crores. India branded formulations grew by almost 12%, excluding impact of NLEM related price cut affecting some key products

Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth

Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.

Q1 results this week: LIC, Adani Ports, IRCTC, Hero MotoCorp, Nykaa and others

Adani Ports, Coal India, Siemens, Hindalco, Linde India, Lloyds Metals, Phoenix Mills, Oil India, Prestige Estates, Aarti Industries, Happiest Minds, Brigade Enterprises, Suven Pharma, Eureka Forbes and others will announce their June quarter results

Q1 earnings: 26 companies that may report over 100% jump in profit

Domestic brokerage Motilal expects Nifty earnings to grow 25% YoY in Q1. Oil and gas sector may report a 3x surge in profit YoY underpinned by the improvement in marketing margins of OMCs. Auto sector’s earnings may surge 11x YoY during the quarter on a low base.

Stocks in news: Tech Mahindra, Lemon Tree, Sula Vineyards, Punjab & Sind Bank, D-link India

The Board of Titagarh Wagons is scheduled to meet on June 10 to consider and approve a proposal to raise funds by issue equity of shares or other securities including through preferential issue.

Zydus Lifesciences Q4 Results: Consolidated net profit dips 25% to Rs 297 crore

Zydus Lifesciences Ltd reported a 25.36% decline in consolidated net profit at Rs 296.6 crore in the fourth quarter ended March 31, 2023 impacted by impairment of goodwill of a wholly-owned subsidiary. The company, which had posted a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the

Q3 results impact: Tata Motors, Zomato among over 35 stock upgrades and downgrades

A team of analysts from global brokerage firm Jefferies has raised the FY23 earnings estimates for 47% of 147 companies under its coverage network. Downgrades were made to 46% of companies, resulting in higher upgrades than downgrades for the first time in five quarters.

Zydus Lifesciences Q3 Results: Firm beats profit view on strong sales

The impact of price hikes to mitigate inflationary pressure would be reflected from the fourth quarter onwards in the consumer wellness segment, which accounted for 10% of total revenues in the third quarter, the company said in an exchange filing.

Stock Radar:Buy Zydus Lifesciences for a target of Rs 435 in next 3-4 weeks, says Gaurav Bissa

Zydus Lifesciences Q1 Results: Net Profit drops 12% YOY to Rs 518 crore

The earnings before interest, tax, depreciation and ammortisation (EBITDA) was Rs 833 crore, a decline of 14.3% YoY. On QoQ, EBITDA rose 16.1%.The EBITDA margins for the quarter dropped 190 basis points to 20.5% in Q1FY23 compared to 24.3% in Q1FY22. On QoQIndia sales saw a drop of 6.5% YoY to Rs 1817 crore in Q1FY23. The formulation business dropped .